肝癌相关抗原KINECTIN基因的重组、表达及其致敏DC抗肝癌活性研究
|
摘要
目的：(1)了解动力素(kinectin)作为肝癌相关抗原在肝癌细胞株BEL-7404中mRNA的表达情况,评价kinectin作为肝癌抗原分子标记以及肝癌免疫治疗特异性靶位的可能性。(2)运用体外基因工程的方法表达、分离纯化kinectin-MBP重组融合蛋白、SMP-30-MBP重组融合蛋白(SMP-30为课题组前期已深入研究的另一肝癌相关抗原,考虑实验室有库存蛋白,本实验顺带比较检测其杀伤效应),探讨kinectin、SMP-30以融合蛋白形式致敏DC后,能否刺激自体T淋巴细胞转化为CTL以及CTL对BEL-7404肝癌细胞有无杀伤作用。(3)免疫组化的方法检测kinectin融合蛋白致敏的DC刺激T细胞亚群活化情况,初步探讨以DC为基础的kinectin瘤苗在肝癌的临床应用价值及其生物学机制。
方法：(1)运用RT-PCR技术检测国产肝癌细胞株BEL-7404 kinectin基因(D2选择剪接区)mRNA的表达,并与肝癌组织、相应癌旁肝组织、正常肝组织比较,了解其表达情况。(2)运用体外蛋白重组技术表达、分离纯化kinectin-MBP融合蛋白、SMP-30-MBP融合蛋白,并与正常人外周血树突状细胞(Dendritic cell,DC)孵育；ELISA检测kinectin-MBP致敏组DC培养上清液IL-12、IFN-γ分泌量；尼龙毛柱分离自体T淋巴细胞后,以致敏DC诱导自体T淋巴细胞为细胞毒性T淋巴细胞(CTL),MTT法检测各组T淋巴细胞增殖情况,LDH 4 h释放法检测CTL对BEL-7404肝癌细胞的细胞毒作用；(3)SupervisionTM,HRP试剂盒免疫组化法检测kinectin-MBP孵育DC组刺激增殖的T细胞中CD4+、CD8+T细胞亚群活化情况,初步判断以DC为基础的kinectin瘤苗在肝细胞癌的生物学作用及机制。
结果：
(1)kinectin(D2选择剪接区)mRNA在BEL-7404肝癌细胞株及两例肝癌组织中呈较强阳性表达,相应癌旁肝组织则呈弱阳性,一例正常肝组织未见表达。
(2)运用体外重组蛋白技术成功表达、分离纯化出kinectin-MBP, SMP-30-MBP, SDS-PAGE电泳检测分子量与预期分子量相吻合。
(3)DC培养、T淋巴细胞增殖、杀伤实验结果：PBMC经rhGM-CSF、rhIL-4诱导培养1周后,出现典型的DC形态；结合FCM细胞表型检测鉴定为DC；DC经Kinectin-MBP致敏后,IL-12、IFN-γ分泌量明显高于MBP孵育组和未致敏DC组(P均＜0.05)；经kinectin-MBP、SMP-30-MBP融合蛋白致敏的DC刺激自体T细胞增殖的能力显著高于MBP孵育DC及非致敏DC组(P均＜0.05)；刺激细胞(DC)占效应细胞(T细胞)比例越大,则增殖能力越强；经kinectin-MBP、SMP-30-MBP融合蛋白致敏的DC诱导的CTL对BEL-7404肝癌细胞均具有较高的杀伤率,在效靶比为25：1时杀伤率达最高峰(分别为65.00±1.47%；64.40±1.40%)。
(4)免疫组化检测结果：Kinectin-MBP蛋白致敏DC刺激的T细胞组CD8+T细胞明显高于MBP孵育DC刺激的T细胞组、非致敏DC刺激组及普通培养T细胞组(P均＜0.05)；各组CD4值之间、CD4／CD8值之间比较,差异无统计学意义(P值均＞0.05)。
结论：kinectin基因(D2选择剪接区)在BEL-7404肝癌细胞株中表达呈较强阳性,具有作为肝癌诊断的辅助分子标记、肝癌免疫治疗特异性靶位的潜在价值。体外蛋白重组技术可成功表达、分离纯化出Kinectin-MBP融合蛋白；经Kinectin-MBP、SMP-30-MBP融合蛋白致敏的DC能有效刺激自体T淋巴细胞的增殖,且可诱导T细胞转化为CTL,后者对BEL-7404肝癌细胞具有较强的细胞毒活性。考虑课到SMP-30的表达特点以及课题组前期实验结果,SMP-30在正常肝组织亦存在阳性表达,故SMP-30能否作为肝癌疫苗尚有待深入研究；但是,结合我们的实验结果,目的蛋白Kinectin-MBP作为肝癌相关抗原可通过致敏DC发挥比较明显的抗肿瘤功能,有望开发为肝癌生物治疗的新疫苗。
Objective:(1) To investigate the mRNA expression of kinectin in hepatocellular carcinoma(HCC) cell line BEL-7404, and evaluate the possibility of immunotherapy as a molecular marker of diagnosis, as well as a liver-specific target for treatment. (2) Kinectin-MBP,SMP-30-MBP recombinant fusion protein were expressed and purified by using genetic engineering methods in vitro respectively. Investigate the ability of pulsed DC with hepatocellular carcinoma-associated antigen kinectin-MBP, SMP-30-MBP to stimulate autologous T lymphocytes into CTL, and also detect its cytotoxicity on BEL-7404. (3) preliminarily explore the clinicial application of kinectin in HCC and its role of its biological mechanism.
Methods:(1) With reverse transcripts polymerase chain reaction(RT-PCR), the kienctin mRNA level of BEL-7404 HCC cell Line, hepatocellular carcinoma tissue, corresponding adjacent non-HCC tissue and normal liver tissue were analyzed. (2) Kinectin-MBP, SMP-30-MBP fusion protein were expressed and purified by means of recombinant protein technology in vitro,and were incubated with human peripheral blood dendritic cells (Dendritic cell,DC),then to induce cytotoxic T lymphocyte (CTL) with pulsed DC.Then cytotoxicity of CTL against BEL-7404 hepatoma cell was assayed by LDH 4 hours release.(3) Detect the proliferation of T cells CD4+, CD8+T cell subset with SupervisionTM, HRP immunohistochemistry, and to determine the role of kinectin in HCC.
Results:(1)The mRNA of Kinectin have a strong expression in BEL-7404 cell line and HCC tissue,low expression in corresponding adjacent non-HCC tissue and normal liver tissue.Successfully expressed and purified kinectin-MBP, SMP-30-MBP by used of recombinant protein technology in vitro, the molecular weight are consistent with the expected molecular weight by electrophoresis.
(2) The results of DC culture, T lymphocyte proliferation, CTL's cytotoxicity toward target cell BEL-7404:PBMCs presented typical morphologic characteristics of DCs after induced by rhGM-CSF and rhIL-4 for 7 days.Comparing with the other two groups, the level of CIL-12 and CIFN-yraised significantly in culture medium supernatants of kinectin-MBP treated group (p<0.05); The proliferation capacity of autologous T cell cultured with the kinectin-MBP, SMP-30-MBP fusion protein-pulsed DC were significantly higher than MBP-pulsed, non-treated cultured DC group (p<0.05). The greater of the ratio of stimulated cells (DC) accounts of effector cells (T cells), the stronger the proliferation ability; higher anti-tumor activity were found by DC-induced The CTL of the BEL-7404 hepatoma cells in kinectin, SMP-30 fusion protein-pulsed groups, the highest killing rate was found when the ratio of effector:target was 25:1 (65.00±1.47%; 64.40±1.40% respectively).
(3) The results of immunohistochemistry:the number of CD8 positive T-cell increased remarkably in kinectin-MBP-DC-T cell group, compared with the MBP-DC-T cell group, DC-T cells group and normal cultured T cells(p<0.05). Furthermore, there are no significant difference of the number of CD4 positive T-cells, CD4/CD8 among of these four group (P> 0.05).
Conclusion:The mRNA level of kinectin (D2 alternative splicing area) showed strong positive expression in the hepatoma cell lines BEL-7404 and HCC tissues. And it can be used as molecular markers for early diagnosis and possible targets for immunotherapy of human HCC. The DCs be pulsed with kinectin, SMP-30 fusion protein can stimulate T lymphocyte proliferation effectively; the pulsed DC can also induce CTL successfully, and have strong cytotoxic activity toward the BEL-7404.The DCs be pulsed of kinectin, fusion protein have a marked anti-tumor function, they are expected to develop the new vaccines for HCC biological therapy.
方法：(1)运用RT-PCR技术检测国产肝癌细胞株BEL-7404 kinectin基因(D2选择剪接区)mRNA的表达,并与肝癌组织、相应癌旁肝组织、正常肝组织比较,了解其表达情况。(2)运用体外蛋白重组技术表达、分离纯化kinectin-MBP融合蛋白、SMP-30-MBP融合蛋白,并与正常人外周血树突状细胞(Dendritic cell,DC)孵育；ELISA检测kinectin-MBP致敏组DC培养上清液IL-12、IFN-γ分泌量；尼龙毛柱分离自体T淋巴细胞后,以致敏DC诱导自体T淋巴细胞为细胞毒性T淋巴细胞(CTL),MTT法检测各组T淋巴细胞增殖情况,LDH 4 h释放法检测CTL对BEL-7404肝癌细胞的细胞毒作用；(3)SupervisionTM,HRP试剂盒免疫组化法检测kinectin-MBP孵育DC组刺激增殖的T细胞中CD4+、CD8+T细胞亚群活化情况,初步判断以DC为基础的kinectin瘤苗在肝细胞癌的生物学作用及机制。
结果：
(1)kinectin(D2选择剪接区)mRNA在BEL-7404肝癌细胞株及两例肝癌组织中呈较强阳性表达,相应癌旁肝组织则呈弱阳性,一例正常肝组织未见表达。
(2)运用体外重组蛋白技术成功表达、分离纯化出kinectin-MBP, SMP-30-MBP, SDS-PAGE电泳检测分子量与预期分子量相吻合。
(3)DC培养、T淋巴细胞增殖、杀伤实验结果：PBMC经rhGM-CSF、rhIL-4诱导培养1周后,出现典型的DC形态；结合FCM细胞表型检测鉴定为DC；DC经Kinectin-MBP致敏后,IL-12、IFN-γ分泌量明显高于MBP孵育组和未致敏DC组(P均＜0.05)；经kinectin-MBP、SMP-30-MBP融合蛋白致敏的DC刺激自体T细胞增殖的能力显著高于MBP孵育DC及非致敏DC组(P均＜0.05)；刺激细胞(DC)占效应细胞(T细胞)比例越大,则增殖能力越强；经kinectin-MBP、SMP-30-MBP融合蛋白致敏的DC诱导的CTL对BEL-7404肝癌细胞均具有较高的杀伤率,在效靶比为25：1时杀伤率达最高峰(分别为65.00±1.47%；64.40±1.40%)。
(4)免疫组化检测结果：Kinectin-MBP蛋白致敏DC刺激的T细胞组CD8+T细胞明显高于MBP孵育DC刺激的T细胞组、非致敏DC刺激组及普通培养T细胞组(P均＜0.05)；各组CD4值之间、CD4／CD8值之间比较,差异无统计学意义(P值均＞0.05)。
结论：kinectin基因(D2选择剪接区)在BEL-7404肝癌细胞株中表达呈较强阳性,具有作为肝癌诊断的辅助分子标记、肝癌免疫治疗特异性靶位的潜在价值。体外蛋白重组技术可成功表达、分离纯化出Kinectin-MBP融合蛋白；经Kinectin-MBP、SMP-30-MBP融合蛋白致敏的DC能有效刺激自体T淋巴细胞的增殖,且可诱导T细胞转化为CTL,后者对BEL-7404肝癌细胞具有较强的细胞毒活性。考虑课到SMP-30的表达特点以及课题组前期实验结果,SMP-30在正常肝组织亦存在阳性表达,故SMP-30能否作为肝癌疫苗尚有待深入研究；但是,结合我们的实验结果,目的蛋白Kinectin-MBP作为肝癌相关抗原可通过致敏DC发挥比较明显的抗肿瘤功能,有望开发为肝癌生物治疗的新疫苗。
Objective:(1) To investigate the mRNA expression of kinectin in hepatocellular carcinoma(HCC) cell line BEL-7404, and evaluate the possibility of immunotherapy as a molecular marker of diagnosis, as well as a liver-specific target for treatment. (2) Kinectin-MBP,SMP-30-MBP recombinant fusion protein were expressed and purified by using genetic engineering methods in vitro respectively. Investigate the ability of pulsed DC with hepatocellular carcinoma-associated antigen kinectin-MBP, SMP-30-MBP to stimulate autologous T lymphocytes into CTL, and also detect its cytotoxicity on BEL-7404. (3) preliminarily explore the clinicial application of kinectin in HCC and its role of its biological mechanism.
Methods:(1) With reverse transcripts polymerase chain reaction(RT-PCR), the kienctin mRNA level of BEL-7404 HCC cell Line, hepatocellular carcinoma tissue, corresponding adjacent non-HCC tissue and normal liver tissue were analyzed. (2) Kinectin-MBP, SMP-30-MBP fusion protein were expressed and purified by means of recombinant protein technology in vitro,and were incubated with human peripheral blood dendritic cells (Dendritic cell,DC),then to induce cytotoxic T lymphocyte (CTL) with pulsed DC.Then cytotoxicity of CTL against BEL-7404 hepatoma cell was assayed by LDH 4 hours release.(3) Detect the proliferation of T cells CD4+, CD8+T cell subset with SupervisionTM, HRP immunohistochemistry, and to determine the role of kinectin in HCC.
Results:(1)The mRNA of Kinectin have a strong expression in BEL-7404 cell line and HCC tissue,low expression in corresponding adjacent non-HCC tissue and normal liver tissue.Successfully expressed and purified kinectin-MBP, SMP-30-MBP by used of recombinant protein technology in vitro, the molecular weight are consistent with the expected molecular weight by electrophoresis.
(2) The results of DC culture, T lymphocyte proliferation, CTL's cytotoxicity toward target cell BEL-7404:PBMCs presented typical morphologic characteristics of DCs after induced by rhGM-CSF and rhIL-4 for 7 days.Comparing with the other two groups, the level of CIL-12 and CIFN-yraised significantly in culture medium supernatants of kinectin-MBP treated group (p<0.05); The proliferation capacity of autologous T cell cultured with the kinectin-MBP, SMP-30-MBP fusion protein-pulsed DC were significantly higher than MBP-pulsed, non-treated cultured DC group (p<0.05). The greater of the ratio of stimulated cells (DC) accounts of effector cells (T cells), the stronger the proliferation ability; higher anti-tumor activity were found by DC-induced The CTL of the BEL-7404 hepatoma cells in kinectin, SMP-30 fusion protein-pulsed groups, the highest killing rate was found when the ratio of effector:target was 25:1 (65.00±1.47%; 64.40±1.40% respectively).
(3) The results of immunohistochemistry:the number of CD8 positive T-cell increased remarkably in kinectin-MBP-DC-T cell group, compared with the MBP-DC-T cell group, DC-T cells group and normal cultured T cells(p<0.05). Furthermore, there are no significant difference of the number of CD4 positive T-cells, CD4/CD8 among of these four group (P> 0.05).
Conclusion:The mRNA level of kinectin (D2 alternative splicing area) showed strong positive expression in the hepatoma cell lines BEL-7404 and HCC tissues. And it can be used as molecular markers for early diagnosis and possible targets for immunotherapy of human HCC. The DCs be pulsed with kinectin, SMP-30 fusion protein can stimulate T lymphocyte proliferation effectively; the pulsed DC can also induce CTL successfully, and have strong cytotoxic activity toward the BEL-7404.The DCs be pulsed of kinectin, fusion protein have a marked anti-tumor function, they are expected to develop the new vaccines for HCC biological therapy.
引文
[1]Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J].CA Cancer J Clin,2005,55:74-108.
[2]L lovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma[J]. Lancet,2003,362:1907-1917.
[3]Dillman RO, Selvan SR, Schiltz PM, et al. Patient specific dendritic cell vaccines for metastatic melanoma[J]. N Engl J Med,2006,355 (11):1179-1181.
[4]Kalinski P, Urban J, Narang R, et al. Dendritic cell based therapeutic cancer vaccines:what we have and what we need[J]. Future Oncol,2009,5(3):379-390.
[5]Burgdorf SK, FischerA, Myschetzky PS, et al. Clinical responses in patientswith advanced colorectal cancer to a dendritic cell based vaccine[J]. Oncol Rep,2008,20(6):1305-1311.
[6]李健.树突状细胞瘤苗制备及应用的研究进展[J].中华医学杂志,2008,32(1)：71-72.
[7]Barbuto J A, Ensina L F, Neves A R, et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer [J]. Cancer Immu-nol Immunother,2004,53:1111-1118.
[8]Wilson N, Mikol C, Donaldson A, et al. Dendritic cell immunother-apy for advanced metastatic melanoma:intermreport[J]. J Immunot-herapy,2005,28 (6):661-667.
[9]YU johns M D, L IU gentao PHD, N G hiushan M S, et al. Aphase Ⅰ trial of intracranial dendritic cell immunotherapy for patients with malignant glioma[J]. Neurosurgery,2006,59:485-485.
[10]张红梅,刘文超,宫卫东,等.全细胞性肿瘤抗原以不同方式负载树突状细胞诱导肝癌特异性T细胞反应[J].中国肿瘤,2009,18(3)：226-229.
[11]Wang HC, Su YR, Han KJ, et al. Multiple variants and a differentialsplicing pattern of kinectin in human hepatocellu-lar carcinoma[J]. Biochem Cell Biol,2004,82(2):321-327.
[12]Toyoshima I, Yu H, Steuer ER, et al. Kinectin, a major kinesin-binding protein on ER[J]. J Cell Biol,1992,118(5):1121-1131.
[13]Futterer A, Kruppa G, Kramer B, et al. Molecular cloning and characterization of human kinectin [J]. Mol Biol Cell,1995,6(2): 161-170.
[14]Yu H, Nicchitta CV, Kumar J, et al. Characterization of kinectin, a kinesin-binding protein:primary sequence and N-terminal topogenic signal analysis [J]. Mol Biol Cell,1995,6(2):171-183.
[15]Kumar J, Erickson HP, Sheetz MP. Ultrastructural and biochemical properties of the 120-kDa form of chick kinectin [J]. J Biol Chem,1998,273(48):31738-31743.
[16]Kamnasaran D. Epigenetic inheritance associated with human chromosome 14[J]. Clin Invest Med,2001,24(3):138-146.
[17]Stenner-Liewen F, Luo G, Sahin U, et al. Definition of tumor-associated Antigens in Hepatocellular Carcinoma. Cancer Epidemiology[J]. Biomarkers & Prevention,2000,9(3):285-290.
[18]谢小薰,王延伟,黎鹏,等.肝细胞癌相关抗原kinectin的血清学分析[J].科学技术与工程,2003,3(2)：143-145.
[19]Salassidis K, Bruch J, Zitzelsberger H, et al. Translocation t (10;14) (q11.2:q22.1) fusing the kinetin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma[J]. Cancer Res,2000,60:2786-2789.
[20]Naoto Hirano, Marcus 0. Butler, Michael S. von Bergwelt-Baildon, et al. Autoantibodies frequently detected in patients with aplastic anemia[J]. Blood,2003,102(13):4567-4575.
[21]冯修高,陈顺乐,陆愉,等.白塞氏病相关抗原的重组表达及抗原性初步分析[J].中国免疫学杂志,2003,19：282-285.
[22]Gure AO, Stockert E, Arden KC, et al. CT10:a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis[J]. Int J Cancer,2000, 85:726-732.
[23]Design and Testing of β-Actin Primers for RT-PCR that Do Not Co-amplify Processed Psedogens[J]. Biotechniques,1997,23:456-460.
[24]Zenthen J, Dzhandzhugazyan K, Hansen MR, et al.The immunogenic properties of human melanomas and melanoma associated antigens recognized by cytotoxic T lymphocytes[J].Bratisl Lek Listy, 1998,99:426-434.
[25]黄天明,黄绍明,莫发荣等.肝癌相关抗原kinectin基因片段的重组表达[J].广西医科大学学报,2006,23(3)：345-347.
[26]Kapust RB, Waugh DS. Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused [J]. Protein Sci,1999,8(8):1668-1674.
[27]张文敏,陈裕庆,张萌等.NY-ESO-1致敏树突状细胞诱导的CTL对肝癌细 胞株的特异性杀伤作用[J].中国肿瘤生物治疗杂志,2009,16(1)：18-23.
[28]Santegoets SJ,Bontkes HJ, Stam AG, et al. Inducing antitumor T cell immunity:comparative functional analysis of interstitial versus langerhans dendritic cells in a human cell line model[J]. J Immunol,2008,180(7):4540-4549.
[29]Mailliard RB, Dallal RM, Son YI, et al. Dendritic cells promoter T-cell survival or death depending upon their maturation atate and presentation of antigen [J]. Immunol Invest,2000,29:177-185.
[30]Holtl L, Zelle-Rieser C, Gander H, et al. Immunotherapy of metastatic renal cell carcinoma with tumoe lysate-pulsed autologous dendritic cells[J].Clin Cancer Res,2002,8:3369-3376.
[31]Butterfield LH, Jilani SM, Chakraborty XG, et al. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus[J]. J immunol,1998, 161:5607-5613.
[32]Butterfield LH, Ribas A, Potter DM, et al. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer [J]. Cancer Immunol Immuno-ther, 2007,56 (12):1931-1943.
[33]Chiriva-Internati M, Grizzi F, Wachtel MS, et al. Biological treatment for liver tumor and new potential biomarkers [J]. Dig-DisSci,2008,53 (3):836-843.
[34]Yin XY, Wang L, Lu MD, et al. Induction of specific cytolytic T lymphocytes using fusions of hepatocellulae carcinoma(HCC) patient-derived dendritic cells and allogeneic HCC cell line[J]. Hepatogastroenterology,2008,55(81):155-159.
[35]Palmer DH, Midgley RS, Mirza N, et al, A phase Ⅱ study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma[J]. Hepatology,2009,49 (1):124-132.
[36]Cao DY, Yang JY, Yue SQ, et al. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma[J]. Cell Immunol,2009,259(1):13-20.
[37]曹天泽,高维实,郭慧军等.诱导高纯度树突状细胞的研究[J].内蒙古医学杂志,2009,41(9)：1025-1028.
[38]Bai L, Feuerer M, Beckhove P, et al. Generation of dendritic cells from human bone marrow mononuclear cells:advantages for clinical application in comparison to peripheral blood monocyte derived cells[J].Int J Oncol,2002,20(2):247-253.
[39]Rosenzwajg M, Canque B,Gluckman JC. Human dendritic cell differentiation pathway from CD34+hematopoietic precursor cells[J]. Blood,1996,87(2):535-544.
[40]王晓,裴学涛,李梁等.脐血CD34+细胞和外周血单核细胞两种来源的树突状细胞特性的比较研究[J].中华血液学杂志,1999,20(11)：583-585.
[41]Banchereau J, Briere F, Caux C, et. al. Immunobiology of dendritic cells[J].Annu Rev Immunol,2000,18:767-811.
[42]HartD.N.J. Dendritic Cells:Unique Leukocyte Populations, Which Control the Primary Immune Response[J]. Blood,1997,90(9):3245- 3287.
[43]叶欣,于连玲,赵梅,等.C57BL／6小鼠树突状细胞的培养及其诱导细胞毒性T淋巴细胞对FBL23细胞杀伤效应的研究[J].泰山医学院学报,2009,30(7)：485-489.
[44]John S. Yu, Gentao Liu, Han Ying, et al. Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cyto-toxic T-Cells in Patients with Malignant Glioma[J]. Cancer Research,2004,64(15):4973-4979.
[45]Maurizio Chiriva-Internati, Weidanz, w z, Yuefei Yu, et al. Sperm Protein 17 is a Suitable Target for Adoptive T-cell-based Immunotherapy in Human Ovarian Cancer[J]. J Immunother,2008, 31 (8):693-703.
[46]Yuji Ueda, Keiji Shimizu, Tsuyoshi Itoh,et al. Induction of peptide-specific Immune response in patients with primary malignant meianoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides[J]. Jpn J Clin Oncol,2007,37 (2):140-145.
[47]周昌菊,马薇,周建大,等.自体宫颈癌-树突状细胞疫苗激活的CTL杀伤效应[J].癌症,2006,25(2)：143-147.
[48]Su Z,Dannull J, Yang BK et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+and CD4+T cell response in patients with metastatic prostate cancer[J].J Immunol,2005,174(6):3798-3807.
[49]陈素钻,郭光华.树突状细胞介导的肿瘤疫苗研究进展[J].汕头大学医学院学报,2004,17(4)：237-239.
[50]Read S, Malmstrom V, Powne F. Cytotoxic T lymphocyte-associ-ated antigen plays an essential role in the function of CD4+CD25 +regulatory cells that control intestinal inflammation [J].J Exp Med,2000,192 (2):295-302.
[51]Wang RF. CD8+regulatory T cells, their suppressive mechan-isms, and regulation in cancer [J]. Hum Immunol,2008,69(11):811-814.
[52]Strauss L, Bergmann C, Szczepanski M, et al.A unique of CD4+CD25+ high FoxP3+reg T cell sereting interleukin-10 transforming growth factou-batal mediates suppression in the tumor micro-environment [J]. Ciln Cancer Res,2007,13:4345-4354.
1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics,2002. CA Cancer J Clin,2005,55:74-108.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet, 2003,362:1907-1917.
3. Steinman RM, Lustig DS, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. J Exp Med,1973,137 (5):1142-1162.
4.阚褚明,陆浩.树突状细胞与肝癌的免疫治疗.医学综述,2007,13(2)： 98-99.
5. Schultze, Nadler LM, Gribben JG, et al. B7 mediated costimulation and the immune response. Blood Review,1996,10:111-127.
6. Santegoets SJ, Bontkes HJ, Stam AG, et al. Inducing antitumor T cell immunity:comparative functional analysis of interstitial versus langerhans dendritic cells in a human cell line model.J Immunol,2008,180(7):4540-4549.
7.刘婷,华川.树突状细胞抗肿瘤免疫的研究进展.重庆医学,2009,38(16)：2090-2092.
8. Chen Z, Moyana T, Saxena A, et al. Efficient antitumor imminity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer,2001,93(1):539-548.
9. SahoUK, Haruka F, ChieH, et al. MHC class Ⅰ-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunol Lett,2003, 89 (2-3):125-131.
10. Banchereal J, Steinman RM, Akabani G, et al. Dendritic cells and the control of immunity. Nature,1998,392(5):245-252.
11. Liu CL, Fan ST, Yamasaki T, et al. Nonresectional therapies for heapatocellular carcinoma:progresss but many stones yet unturned![J]. Castroenterology,1997,112(11):656-659.
12.李明松,袁爱力.肝癌患者外周血树突状细胞免疫状态的研究.中国癌症杂志,1998,8(2)：85-87.
13. Basu S, Bimder RJ, Suto R, et al.Necrotic but not apoptotic cell death releases heat shock proteins,which deliver a partial maturation signal to dendritic cells and activate the NF-kappa
B pathway. Immumol,2000,12(2):1539-1546.
14. Ninomiya SK, Fazle MD, Akbar RM, et al. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. Hepatology,1999,31 (7):323-331.
15. Labeur M, Boerman O, Collins J, et al. Generation tumor immunity by bone marrow derived dendritic cells correlates with the dendri-tic cell maturation stage. Immunol,1999,162(4):168-175.
16. Mellman I, Steinman RM. Dendritic cells:specialized and regula-ted antigen processing machines.Cell,2001,106:255-258.
17. Kakumu S, Ito S, Ishikawa T, et al.Decreased function of peri-pheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol,2000,15:431-436.
18.汤钊酞.肝癌患者的免疫功能测定.临床肝癌治疗学,上海：上海科技教育出版社,2001：56-57.
19. Chen S, Akbar SM,Tanimoto K, et al. Absence of CD83-Positive mature and Activated dendritic cells at cancer nodules from Patients with hePatocellular carcinoma:relevance to hepatocarcinogenesis. Can-cer Lett,2000,148(1):49-57.
20.邱双健.树突状细胞与肝癌的免疫逃逸.世界华人消化杂志,2005,13(4)：429-431.
21.Beckebaum S, Zhang X, Chen X, et al, Increased levels of interl-eukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phe- notype of circulating dendritie cell subsets.Clin, Cancer Res, 2004,10:7260-7269.
22. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95(Ap0-1/Fas)ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med,1996,2:1361-1366.
23. Nagao M, Nakaiioa Y, Kanehiro H, et al. The impact of interferon gama receptor expression on the mechanism of escape from host immune surveillance in hepatoeellular carcinorna. HePatology, 2000,32:491-500.
24. Friedl J, Stift A, Paolini p, et al. Tumor antigen Pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymph-ocytes in human hepatocellular cancer. Cancer Biother Radiopharm 2000,15:477-486.
25.Um SH, Mulhall, Alisa A, et al. Alpha-fetoprotein impairs APC function and induces their apoptosis. J Immunol 2004,173:1772-1778.
26. Mayordomo J, Zorina T, Storkus WJ, et al. Bone marrow derived den-dritic cells serve as potent adjuvants for peptide based antitu-mor vaccines. Stem Cells,1997,15(3):94-103.
27. Yasuda T, KamigakiT, Nakamura T, et al. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes againstmu-rine colon cancer:a comparative analysis of antigen loading me-thods for the vaccination of immunotherapeutic dendritic cells. Oncol Rep,2006,16 (6):1317-1324.
28. Mahdian R, Kokhaei P, Najar HM, et al. Dendritic cells pulsed with
lysate of allogeneic tumor cells are capable of stimulating MHC-restricted antigen-specific antitumor T cells. Med Oncol 2006, 23(2):273-282.
29. Holtl L, Zelle-RieserC, Gander H, et al. Immunotherapy of metas-tatic renal cell carcinoma with tumor Lysate-pulsed autologous dendritic cells.Clin CancerRes,2002,8(7):3369-3376.
30. TatsumiT, Takehara T, Yamaguchi S, et al Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liv-er tumor. Hepatology,2007,45(1):22-30.
31.Ojima T, Iwahashi M, Nakamura M, et al Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon can-cer using genetically modified dendritic cells that express CEA and Thelper-type 1 cytokines in CEA transgenicmice. Int J Cancer, 2007,120(3):585-593.
32. Zhang JK, Li J, Zhang J, et al. Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo. World J Gastroente-rol,2003,9 (3):479-484.
33. Thery C, Duban L, Segura E, et al. Indirect activation of naive CD4+T cells by dendritic cell-derived exosomes. Nat Immunol, 2002,3(12):1156-1162.
34.张红梅,张力旺,任军等.树突状细胞-肝癌细胞株HepG2融合细胞来源的exosome抗肝癌效应的实验研究.Modern Oncology,2006,14(9)：1047-1051.
35. Mou SL, Cai JR, Peng HS, et al. Evaluation of MAGE-1 and MAGE-3 as tumour specific markers to detect blood dissemination of hepatocellular carcinoma cells.Cancer,2002,86(3):110-116.
36. Ochsenbein S, Sierro B, Odermatt M, et al. Roles of tumour localiz-ation, second signals and cross priming in cytotoxic T cell ind-uction. Nature,2001,411(6):1058-1064.
37. Chen CH, Huang GT, Lee HS, et al. High frequency of expression of MAGE genes in human hepatocellular carcinoma. Liver,1999,19 (10):110-114.
38. Alessandro Z,Todrik S, hardwick N, et al. Ex vivo characterizat-ion of tumor derived melanoma antigen encoding gene specific CD8+cells in patients with hepatocellular carcinoma. Hepatology, 2004,40 (3):102-109.
39. Yoshiyuki K, Toshihiro H, Kazuhiro N, et al. Expression of MAGE, GAGE and BAGE genes in human liver diseases:utility as molecular markers for hepatocellular carcinoma. J Hepatol,2000,32(6):612-617.
40. Ray CF, Francisco L, Albert M, et al. Dendritomas formed by fusion of mature dendritic cells with allogenic human hepatocellular carcinoma cells activate autologous cytotoxic T lymphocytes. Im-munology letters,2002,83(1):101-109.
41. Iwashita Y, Todrik S, Hardwick N, et al. A phase I study of autologous dendritic cell based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunology, Immunothe-rapy,2003,52 (3):155-161.
42.Butterfield LH, Koh A, Meng W, et al. Generation of human T cell responses to an HLA-A2.1 restricted peptide epitope from α fetoprotein. Cancer Res,1999,59(2):3134-3142.
43. Butterfield LH, Koh A, Meng W, et al.T cell responses to HLA-A*0201 restricted peptides derived from α-fetoprotein. Imm-unol,2001,15(27):323-328.
44. Wilson S, Meng LH, Justin B, et al. fine specificity analysis of an HLA-A2.1 restricted immunodominant T cell epitope deriv-ed from human a-fetoprotein. Molecular Immunology,2001,37(7):943-950.
45. Lee WC, Wang HC, Hung CF, et al. Vaccination of advanced hepato-cellular carcinoma patients with tumor lysate-pulsed dendritic cells:a clinical trial. Immunother,2005,28(5):496-504.
46. Gonzalez-CarmonaMA, MartenA, HoffmannP, et al. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells.Liver Int 2006,26(3):369-379.
47. Palmer DH, Midgley RS, Mirza N, et al, A phase Ⅱ study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology,2009,49 (1):124-132.
48. Cao DY, Yang JY, Yue SQ, et al. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and aut-ologous tumor cells as potential cancer vaccines against hepato-cellular carcinoma. Cell Immunol,2009,259(1):13-20.
49. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant-glioma patients with peptide-pulsed dendritic cells elicits sys-temic cytotoxicity and intracranial T-cell infiltration[J]. Cancer Res,2001,61:842-847.
50. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res,2001,61:8513-8519.
51.Ludewig B, Ochsenbein AF, odermatt B, et al. Immunotherapy with dendritic cells directed against tumor antigens shared with no-rmal host cells results in severe autoimmune disease. J Exp Med,2000,191:795-804.
[2]L lovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma[J]. Lancet,2003,362:1907-1917.
[3]Dillman RO, Selvan SR, Schiltz PM, et al. Patient specific dendritic cell vaccines for metastatic melanoma[J]. N Engl J Med,2006,355 (11):1179-1181.
[4]Kalinski P, Urban J, Narang R, et al. Dendritic cell based therapeutic cancer vaccines:what we have and what we need[J]. Future Oncol,2009,5(3):379-390.
[5]Burgdorf SK, FischerA, Myschetzky PS, et al. Clinical responses in patientswith advanced colorectal cancer to a dendritic cell based vaccine[J]. Oncol Rep,2008,20(6):1305-1311.
[6]李健.树突状细胞瘤苗制备及应用的研究进展[J].中华医学杂志,2008,32(1)：71-72.
[7]Barbuto J A, Ensina L F, Neves A R, et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer [J]. Cancer Immu-nol Immunother,2004,53:1111-1118.
[8]Wilson N, Mikol C, Donaldson A, et al. Dendritic cell immunother-apy for advanced metastatic melanoma:intermreport[J]. J Immunot-herapy,2005,28 (6):661-667.
[9]YU johns M D, L IU gentao PHD, N G hiushan M S, et al. Aphase Ⅰ trial of intracranial dendritic cell immunotherapy for patients with malignant glioma[J]. Neurosurgery,2006,59:485-485.
[10]张红梅,刘文超,宫卫东,等.全细胞性肿瘤抗原以不同方式负载树突状细胞诱导肝癌特异性T细胞反应[J].中国肿瘤,2009,18(3)：226-229.
[11]Wang HC, Su YR, Han KJ, et al. Multiple variants and a differentialsplicing pattern of kinectin in human hepatocellu-lar carcinoma[J]. Biochem Cell Biol,2004,82(2):321-327.
[12]Toyoshima I, Yu H, Steuer ER, et al. Kinectin, a major kinesin-binding protein on ER[J]. J Cell Biol,1992,118(5):1121-1131.
[13]Futterer A, Kruppa G, Kramer B, et al. Molecular cloning and characterization of human kinectin [J]. Mol Biol Cell,1995,6(2): 161-170.
[14]Yu H, Nicchitta CV, Kumar J, et al. Characterization of kinectin, a kinesin-binding protein:primary sequence and N-terminal topogenic signal analysis [J]. Mol Biol Cell,1995,6(2):171-183.
[15]Kumar J, Erickson HP, Sheetz MP. Ultrastructural and biochemical properties of the 120-kDa form of chick kinectin [J]. J Biol Chem,1998,273(48):31738-31743.
[16]Kamnasaran D. Epigenetic inheritance associated with human chromosome 14[J]. Clin Invest Med,2001,24(3):138-146.
[17]Stenner-Liewen F, Luo G, Sahin U, et al. Definition of tumor-associated Antigens in Hepatocellular Carcinoma. Cancer Epidemiology[J]. Biomarkers & Prevention,2000,9(3):285-290.
[18]谢小薰,王延伟,黎鹏,等.肝细胞癌相关抗原kinectin的血清学分析[J].科学技术与工程,2003,3(2)：143-145.
[19]Salassidis K, Bruch J, Zitzelsberger H, et al. Translocation t (10;14) (q11.2:q22.1) fusing the kinetin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma[J]. Cancer Res,2000,60:2786-2789.
[20]Naoto Hirano, Marcus 0. Butler, Michael S. von Bergwelt-Baildon, et al. Autoantibodies frequently detected in patients with aplastic anemia[J]. Blood,2003,102(13):4567-4575.
[21]冯修高,陈顺乐,陆愉,等.白塞氏病相关抗原的重组表达及抗原性初步分析[J].中国免疫学杂志,2003,19：282-285.
[22]Gure AO, Stockert E, Arden KC, et al. CT10:a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis[J]. Int J Cancer,2000, 85:726-732.
[23]Design and Testing of β-Actin Primers for RT-PCR that Do Not Co-amplify Processed Psedogens[J]. Biotechniques,1997,23:456-460.
[24]Zenthen J, Dzhandzhugazyan K, Hansen MR, et al.The immunogenic properties of human melanomas and melanoma associated antigens recognized by cytotoxic T lymphocytes[J].Bratisl Lek Listy, 1998,99:426-434.
[25]黄天明,黄绍明,莫发荣等.肝癌相关抗原kinectin基因片段的重组表达[J].广西医科大学学报,2006,23(3)：345-347.
[26]Kapust RB, Waugh DS. Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused [J]. Protein Sci,1999,8(8):1668-1674.
[27]张文敏,陈裕庆,张萌等.NY-ESO-1致敏树突状细胞诱导的CTL对肝癌细 胞株的特异性杀伤作用[J].中国肿瘤生物治疗杂志,2009,16(1)：18-23.
[28]Santegoets SJ,Bontkes HJ, Stam AG, et al. Inducing antitumor T cell immunity:comparative functional analysis of interstitial versus langerhans dendritic cells in a human cell line model[J]. J Immunol,2008,180(7):4540-4549.
[29]Mailliard RB, Dallal RM, Son YI, et al. Dendritic cells promoter T-cell survival or death depending upon their maturation atate and presentation of antigen [J]. Immunol Invest,2000,29:177-185.
[30]Holtl L, Zelle-Rieser C, Gander H, et al. Immunotherapy of metastatic renal cell carcinoma with tumoe lysate-pulsed autologous dendritic cells[J].Clin Cancer Res,2002,8:3369-3376.
[31]Butterfield LH, Jilani SM, Chakraborty XG, et al. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus[J]. J immunol,1998, 161:5607-5613.
[32]Butterfield LH, Ribas A, Potter DM, et al. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer [J]. Cancer Immunol Immuno-ther, 2007,56 (12):1931-1943.
[33]Chiriva-Internati M, Grizzi F, Wachtel MS, et al. Biological treatment for liver tumor and new potential biomarkers [J]. Dig-DisSci,2008,53 (3):836-843.
[34]Yin XY, Wang L, Lu MD, et al. Induction of specific cytolytic T lymphocytes using fusions of hepatocellulae carcinoma(HCC) patient-derived dendritic cells and allogeneic HCC cell line[J]. Hepatogastroenterology,2008,55(81):155-159.
[35]Palmer DH, Midgley RS, Mirza N, et al, A phase Ⅱ study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma[J]. Hepatology,2009,49 (1):124-132.
[36]Cao DY, Yang JY, Yue SQ, et al. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma[J]. Cell Immunol,2009,259(1):13-20.
[37]曹天泽,高维实,郭慧军等.诱导高纯度树突状细胞的研究[J].内蒙古医学杂志,2009,41(9)：1025-1028.
[38]Bai L, Feuerer M, Beckhove P, et al. Generation of dendritic cells from human bone marrow mononuclear cells:advantages for clinical application in comparison to peripheral blood monocyte derived cells[J].Int J Oncol,2002,20(2):247-253.
[39]Rosenzwajg M, Canque B,Gluckman JC. Human dendritic cell differentiation pathway from CD34+hematopoietic precursor cells[J]. Blood,1996,87(2):535-544.
[40]王晓,裴学涛,李梁等.脐血CD34+细胞和外周血单核细胞两种来源的树突状细胞特性的比较研究[J].中华血液学杂志,1999,20(11)：583-585.
[41]Banchereau J, Briere F, Caux C, et. al. Immunobiology of dendritic cells[J].Annu Rev Immunol,2000,18:767-811.
[42]HartD.N.J. Dendritic Cells:Unique Leukocyte Populations, Which Control the Primary Immune Response[J]. Blood,1997,90(9):3245- 3287.
[43]叶欣,于连玲,赵梅,等.C57BL／6小鼠树突状细胞的培养及其诱导细胞毒性T淋巴细胞对FBL23细胞杀伤效应的研究[J].泰山医学院学报,2009,30(7)：485-489.
[44]John S. Yu, Gentao Liu, Han Ying, et al. Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cyto-toxic T-Cells in Patients with Malignant Glioma[J]. Cancer Research,2004,64(15):4973-4979.
[45]Maurizio Chiriva-Internati, Weidanz, w z, Yuefei Yu, et al. Sperm Protein 17 is a Suitable Target for Adoptive T-cell-based Immunotherapy in Human Ovarian Cancer[J]. J Immunother,2008, 31 (8):693-703.
[46]Yuji Ueda, Keiji Shimizu, Tsuyoshi Itoh,et al. Induction of peptide-specific Immune response in patients with primary malignant meianoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides[J]. Jpn J Clin Oncol,2007,37 (2):140-145.
[47]周昌菊,马薇,周建大,等.自体宫颈癌-树突状细胞疫苗激活的CTL杀伤效应[J].癌症,2006,25(2)：143-147.
[48]Su Z,Dannull J, Yang BK et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+and CD4+T cell response in patients with metastatic prostate cancer[J].J Immunol,2005,174(6):3798-3807.
[49]陈素钻,郭光华.树突状细胞介导的肿瘤疫苗研究进展[J].汕头大学医学院学报,2004,17(4)：237-239.
[50]Read S, Malmstrom V, Powne F. Cytotoxic T lymphocyte-associ-ated antigen plays an essential role in the function of CD4+CD25 +regulatory cells that control intestinal inflammation [J].J Exp Med,2000,192 (2):295-302.
[51]Wang RF. CD8+regulatory T cells, their suppressive mechan-isms, and regulation in cancer [J]. Hum Immunol,2008,69(11):811-814.
[52]Strauss L, Bergmann C, Szczepanski M, et al.A unique of CD4+CD25+ high FoxP3+reg T cell sereting interleukin-10 transforming growth factou-batal mediates suppression in the tumor micro-environment [J]. Ciln Cancer Res,2007,13:4345-4354.
1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics,2002. CA Cancer J Clin,2005,55:74-108.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet, 2003,362:1907-1917.
3. Steinman RM, Lustig DS, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. J Exp Med,1973,137 (5):1142-1162.
4.阚褚明,陆浩.树突状细胞与肝癌的免疫治疗.医学综述,2007,13(2)： 98-99.
5. Schultze, Nadler LM, Gribben JG, et al. B7 mediated costimulation and the immune response. Blood Review,1996,10:111-127.
6. Santegoets SJ, Bontkes HJ, Stam AG, et al. Inducing antitumor T cell immunity:comparative functional analysis of interstitial versus langerhans dendritic cells in a human cell line model.J Immunol,2008,180(7):4540-4549.
7.刘婷,华川.树突状细胞抗肿瘤免疫的研究进展.重庆医学,2009,38(16)：2090-2092.
8. Chen Z, Moyana T, Saxena A, et al. Efficient antitumor imminity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer,2001,93(1):539-548.
9. SahoUK, Haruka F, ChieH, et al. MHC class Ⅰ-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunol Lett,2003, 89 (2-3):125-131.
10. Banchereal J, Steinman RM, Akabani G, et al. Dendritic cells and the control of immunity. Nature,1998,392(5):245-252.
11. Liu CL, Fan ST, Yamasaki T, et al. Nonresectional therapies for heapatocellular carcinoma:progresss but many stones yet unturned![J]. Castroenterology,1997,112(11):656-659.
12.李明松,袁爱力.肝癌患者外周血树突状细胞免疫状态的研究.中国癌症杂志,1998,8(2)：85-87.
13. Basu S, Bimder RJ, Suto R, et al.Necrotic but not apoptotic cell death releases heat shock proteins,which deliver a partial maturation signal to dendritic cells and activate the NF-kappa
B pathway. Immumol,2000,12(2):1539-1546.
14. Ninomiya SK, Fazle MD, Akbar RM, et al. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. Hepatology,1999,31 (7):323-331.
15. Labeur M, Boerman O, Collins J, et al. Generation tumor immunity by bone marrow derived dendritic cells correlates with the dendri-tic cell maturation stage. Immunol,1999,162(4):168-175.
16. Mellman I, Steinman RM. Dendritic cells:specialized and regula-ted antigen processing machines.Cell,2001,106:255-258.
17. Kakumu S, Ito S, Ishikawa T, et al.Decreased function of peri-pheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol,2000,15:431-436.
18.汤钊酞.肝癌患者的免疫功能测定.临床肝癌治疗学,上海：上海科技教育出版社,2001：56-57.
19. Chen S, Akbar SM,Tanimoto K, et al. Absence of CD83-Positive mature and Activated dendritic cells at cancer nodules from Patients with hePatocellular carcinoma:relevance to hepatocarcinogenesis. Can-cer Lett,2000,148(1):49-57.
20.邱双健.树突状细胞与肝癌的免疫逃逸.世界华人消化杂志,2005,13(4)：429-431.
21.Beckebaum S, Zhang X, Chen X, et al, Increased levels of interl-eukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phe- notype of circulating dendritie cell subsets.Clin, Cancer Res, 2004,10:7260-7269.
22. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95(Ap0-1/Fas)ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med,1996,2:1361-1366.
23. Nagao M, Nakaiioa Y, Kanehiro H, et al. The impact of interferon gama receptor expression on the mechanism of escape from host immune surveillance in hepatoeellular carcinorna. HePatology, 2000,32:491-500.
24. Friedl J, Stift A, Paolini p, et al. Tumor antigen Pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymph-ocytes in human hepatocellular cancer. Cancer Biother Radiopharm 2000,15:477-486.
25.Um SH, Mulhall, Alisa A, et al. Alpha-fetoprotein impairs APC function and induces their apoptosis. J Immunol 2004,173:1772-1778.
26. Mayordomo J, Zorina T, Storkus WJ, et al. Bone marrow derived den-dritic cells serve as potent adjuvants for peptide based antitu-mor vaccines. Stem Cells,1997,15(3):94-103.
27. Yasuda T, KamigakiT, Nakamura T, et al. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes againstmu-rine colon cancer:a comparative analysis of antigen loading me-thods for the vaccination of immunotherapeutic dendritic cells. Oncol Rep,2006,16 (6):1317-1324.
28. Mahdian R, Kokhaei P, Najar HM, et al. Dendritic cells pulsed with
lysate of allogeneic tumor cells are capable of stimulating MHC-restricted antigen-specific antitumor T cells. Med Oncol 2006, 23(2):273-282.
29. Holtl L, Zelle-RieserC, Gander H, et al. Immunotherapy of metas-tatic renal cell carcinoma with tumor Lysate-pulsed autologous dendritic cells.Clin CancerRes,2002,8(7):3369-3376.
30. TatsumiT, Takehara T, Yamaguchi S, et al Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liv-er tumor. Hepatology,2007,45(1):22-30.
31.Ojima T, Iwahashi M, Nakamura M, et al Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon can-cer using genetically modified dendritic cells that express CEA and Thelper-type 1 cytokines in CEA transgenicmice. Int J Cancer, 2007,120(3):585-593.
32. Zhang JK, Li J, Zhang J, et al. Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo. World J Gastroente-rol,2003,9 (3):479-484.
33. Thery C, Duban L, Segura E, et al. Indirect activation of naive CD4+T cells by dendritic cell-derived exosomes. Nat Immunol, 2002,3(12):1156-1162.
34.张红梅,张力旺,任军等.树突状细胞-肝癌细胞株HepG2融合细胞来源的exosome抗肝癌效应的实验研究.Modern Oncology,2006,14(9)：1047-1051.
35. Mou SL, Cai JR, Peng HS, et al. Evaluation of MAGE-1 and MAGE-3 as tumour specific markers to detect blood dissemination of hepatocellular carcinoma cells.Cancer,2002,86(3):110-116.
36. Ochsenbein S, Sierro B, Odermatt M, et al. Roles of tumour localiz-ation, second signals and cross priming in cytotoxic T cell ind-uction. Nature,2001,411(6):1058-1064.
37. Chen CH, Huang GT, Lee HS, et al. High frequency of expression of MAGE genes in human hepatocellular carcinoma. Liver,1999,19 (10):110-114.
38. Alessandro Z,Todrik S, hardwick N, et al. Ex vivo characterizat-ion of tumor derived melanoma antigen encoding gene specific CD8+cells in patients with hepatocellular carcinoma. Hepatology, 2004,40 (3):102-109.
39. Yoshiyuki K, Toshihiro H, Kazuhiro N, et al. Expression of MAGE, GAGE and BAGE genes in human liver diseases:utility as molecular markers for hepatocellular carcinoma. J Hepatol,2000,32(6):612-617.
40. Ray CF, Francisco L, Albert M, et al. Dendritomas formed by fusion of mature dendritic cells with allogenic human hepatocellular carcinoma cells activate autologous cytotoxic T lymphocytes. Im-munology letters,2002,83(1):101-109.
41. Iwashita Y, Todrik S, Hardwick N, et al. A phase I study of autologous dendritic cell based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunology, Immunothe-rapy,2003,52 (3):155-161.
42.Butterfield LH, Koh A, Meng W, et al. Generation of human T cell responses to an HLA-A2.1 restricted peptide epitope from α fetoprotein. Cancer Res,1999,59(2):3134-3142.
43. Butterfield LH, Koh A, Meng W, et al.T cell responses to HLA-A*0201 restricted peptides derived from α-fetoprotein. Imm-unol,2001,15(27):323-328.
44. Wilson S, Meng LH, Justin B, et al. fine specificity analysis of an HLA-A2.1 restricted immunodominant T cell epitope deriv-ed from human a-fetoprotein. Molecular Immunology,2001,37(7):943-950.
45. Lee WC, Wang HC, Hung CF, et al. Vaccination of advanced hepato-cellular carcinoma patients with tumor lysate-pulsed dendritic cells:a clinical trial. Immunother,2005,28(5):496-504.
46. Gonzalez-CarmonaMA, MartenA, HoffmannP, et al. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells.Liver Int 2006,26(3):369-379.
47. Palmer DH, Midgley RS, Mirza N, et al, A phase Ⅱ study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology,2009,49 (1):124-132.
48. Cao DY, Yang JY, Yue SQ, et al. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and aut-ologous tumor cells as potential cancer vaccines against hepato-cellular carcinoma. Cell Immunol,2009,259(1):13-20.
49. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant-glioma patients with peptide-pulsed dendritic cells elicits sys-temic cytotoxicity and intracranial T-cell infiltration[J]. Cancer Res,2001,61:842-847.
50. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res,2001,61:8513-8519.
51.Ludewig B, Ochsenbein AF, odermatt B, et al. Immunotherapy with dendritic cells directed against tumor antigens shared with no-rmal host cells results in severe autoimmune disease. J Exp Med,2000,191:795-804.